Contract Deobligations Alert — March 26, 2026

Westat ($505M obligated, $960M options), PPD ($126M full commitment), and Advanced Technology ($161M biotech) provide multi-year PATH/COVID R&D cashflows through 2029.

AATD LLC's $138M obligated/$423M potential delivery order for endpoints IT shows 88% outlay progress ($122M disbursed) with set-aside protections through 2026.

Acacia's $832M obligation (94% outlayed) for unaccompanied children legal aid via DOI confirms program continuity but no equity exposure.

Low early outlays in BARDA biotech ($240k vs $161M) signal potential delays over 4+ year periods.

COVID-19 R&D focus vulnerable to shifting pandemic priorities through 2029.

Heavy subawards (Acacia 119/$285M; Westat 12/$27M) risk disputes/delays.

$607M unexercised options across Westat ($455M), AATD ($285M) offer obligation upside in R&D/IT.

BARDA/HHS biotech awards signal follow-on potential in immunogenicity/COVID R&D.

HHS contracts total $793M (45% of stream) across PATH, biotech, COVID assays with extensions to 2029.

AATD's SDVOSB/8(a) IT win ($423M potential) highlights protected VA endpoints services market.

{"entity"=>"Westat, Inc.", "reason"=>"$960M PATH options + ongoing outlays through 2028 represent largest upside.", "trigger"=>"option funding notices >$455M"}

{"entity"=>"AATD LLC", "reason"=>"88% outlay pace + $285M options in SDVOSB VA IT.", "trigger"=>"obligation increases beyond $138M"}

{"entity"=>"BARDA Programs", "reason"=>"Back-to-back biotech/COVID awards ($287M total) indicate pipeline momentum.", "trigger"=>"new non-competed task orders"}